|
Index of reports
> Cases resulting in disability (7)
> Cases with Breast Cancer in Situ (2)
Below is the selection of adverse event reports related to Premarin (Conjugated Estrogens) that includes cases resulting in disability where reactions include breast cancer in situ.
Adverse event in female receiving Premarin (Conjugated Estrogens)
Reported by a individual with unspecified qualification from United States on 2007-03-08
Patient: female
Adverse reactions / side effects: Nipple Pain, Breast Cancer in Situ, Electrocardiogram Ambulatory Abnormal, Mammogram Abnormal, Laboratory Test Abnormal, Palpitations, Uterine Leiomyoma, Chest Pain, Injury, Ventricular Extrasystoles, Intervertebral Disc Protrusion, Nausea, Supraventricular Extrasystoles, Arrhythmia, Emotional Distress, Anxiety, Rhinitis Allergic, Syncope, Presyncope, Scar
Adverse event resulted in: disablity
Suspect drug(s):
Climara ^schering^
Dosage: 0.1 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1997-07-01
Estrace
Dosage: 1 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1997-06-27
Premarin
Dosage: 0.062 mg, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1996-03-08
Vivelle
Dosage: 0.05 mg/day, unk
Indication: Hormone Replacement Therapy
Start date: 1996-06-20
Adverse event in 51 year old female receiving Premarin (Conjugated Estrogens)
Reported by a individual with unspecified qualification from United States on 2007-02-28
Patient: 51 year old female, weighing 88.4 kg (194.6 pounds)
Adverse reactions / side effects: Vocal Cord Thickening, Electrocardiogram ST-T Change, Breast Cancer in Situ, Hot Flush, Breast Cyst, Palpitations, Fibroadenoma of Breast, Breast Microcalcification, Injury, Ventricular Extrasystoles, Dyspnoea, Mastitis, Malignant Breast Lump Removal, Mammary Duct Ectasia, Anxiety, Emotional Distress, Dysphonia, Insomnia, Breast Tenderness, Breast Abscess, Abscess, Scar
Adverse event resulted in: disablity
Suspect drug(s):
Alora
Climara ^schering^
Dosage: 0.1 mg/day, unk
Indication: Hormone Replacement Therapy
Premarin
Dosage: 0.625 mg/day, 3 q 4 weeks
Indication: Hormone Replacement Therapy
End date: 1983-01-01
Vivelle
Indication: Hormone Replacement Therapy
Vivelle-DOT
Dosage: 0.025 mg/day, q3 days
Indication: Hormone Replacement Therapy
Start date: 1999-06-29
End date: 2001-05-03
Other drugs received by patient: Bellergal-S
|
